SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced the appointment of Ian Clements, Ph.D., as chief financial officer.
“Marea is entering a period of growth and rapid advancement to clinical milestones following our recent launch, completion of our Series B financing, and with our lead program, MAR001, advancing in Phase 2 clinical development,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “It is a pleasure to welcome Ian during this important time. We are confident that his financial expertise and business acumen will help propel our efforts as we aim to accelerate a new generation of medicines that treat key unaddressed drivers of cardiometabolic disease.”
Dr. Clements brings extensive biopharmaceutical business leadership experience to Marea. Prior to joining Marea, Dr. Clements served as chief financial officer of Mirum Pharmaceuticals, from founding through its successful evolution to a publicly listed commercial stage company, overseeing financial reporting, planning and budgeting, accounting, internal controls, corporate affairs, investor relations, legal, facilities, and information technology functions. Before Mirum, Dr. Clements served as vice president of investor relations at Dermira, Inc. and as vice president, investor relations and corporate communications at Tobira. Prior to that, he was head of investor relations and corporate communications at Avanir Pharmaceuticals. Dr. Clements has also held leadership positions at Sequenom, a genetic analysis and diagnostics company, and The Trout Group, where he managed west coast operations for life sciences investor relations. Dr. Clements received a Ph.D. in chemistry from the University of Manchester, an M.B.A. from the Open University in the United Kingdom and a B.Sc. in chemistry from Staffordshire University.
“Marea is a compelling company that holds remarkable promise and is well-positioned to transform the way cardiometabolic diseases are treated. I am enthusiastic about joining this skilled team, and am impressed by their scientific rigor, their passion, and their patient focus,” said Dr. Clements. “I look forward to working with the team to build on the company’s strong foundation and to help realize MAR001’s potential in cardiometabolic diseases and delivering value to patients and shareholders.”
About Marea
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
